Bionano Laboratories offers unlimited clinical support to patients and providers through access to our genetic counselors who can discuss testing capabilities, strategy, informed consent, and results.
Providers can call our genetic counselors at
Common variants in the following genes are assessed:
CYP2D6, CYP3A5, CYP2C19, SLCO1B1, CYP2C9, COMT, VKORC1, CYP2B6, CYP1A2, OPRM1, CYP3A4, ABCG2, F2, F5, HLA-A *31:01, HLA-B*15:02, ABCB1, ADRA2A, APOE (526C>T), CES1A1, DRD2, HTR2A, MTHFR (C677T), SLC6A4, UGT1A4, UGT2B15
This test is comprised of the Veridose Core and Veridose CYP2D6 CNV panels developed by Agena. The genomic regions listed in this report were tested using the Agena MassARRAY® System. There is a possibility that the tested individual is a carrier for additional undetected variants that may affect results. Allergic reactions cannot be detected by this genetic test. The test does not detect all known variants in the genes tested.
All medications known to have a firm association with a specific genotype can be found using our GeneSearch tool, under the “Pharmacogenetics Medication Search Tool” tab located here.
Ordering providers are encouraged to submit a patient’s current medication list at the time of the test request. Once results are issued, you will find that our reports utilize a red-green-yellow categorization system to make results visually simple. Additionally, any personalized information available regarding the submitted medication list is described. This may include drug-gene interaction information or published dosing guidelines. Lastly, both providers and patients have access to a certified team of genetic counselors to review results at their convenience.
To schedule an appointment, please call 801.931.6191 or schedule online.
No. If other tests are being ordered at the same time, such as FirstStepDx PLUS (chromosomal microarray) or Fragile X syndrome testing, PGx can be performed on the same cheek swab sample.
